Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...
The World’s First Crispr Drug Gets a Slow Start
The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients ...
The Motley Fool on MSN14d
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
What's going on with CRISPR Therapeutics ( CRSP -0.99%)? The company's shares have been southbound for the better part of ...
Pharmaceutical Technology20h
CTX-131 by CRISPR Therapeutics for T-Cell Lymphomas: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...
Business Wire29d
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with ...
The Most Important Breakthroughs of 2024
This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there ...
Business Insider28d
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle cell disease or transfusion-dependent beta thalassemia. CASGEVY is the ...